Part 6 — From lab to child

22. The translation pipeline

flowchart LR
    A["<b>Discovery</b><br/>hit in cells"] --> B["<b>Preclinical</b><br/>animal efficacy<br/>+ toxicology"]
    B --> C["<b>IND</b><br/>regulatory permission<br/>to dose a human"]
    C --> D["<b>Phase 1</b><br/>safety"]
    D --> E["<b>Phase 2</b><br/>does it work?"]
    E --> F["<b>Phase 3</b><br/>large confirmation"]
    F --> G["<b>Approval</b>"]
    C -.->|"ultra-rare<br/>alternate routes"| H["<b>N-of-1 protocol</b><br/><b>Expanded access</b><br/><i>Module 23</i>"]

The standard path takes 10–15 years and costs hundreds of millions. For a disease with a few dozen known patients worldwide, no company will run it — there is no commercial return. This is the fundamental economic problem of ultra-rare disease, and it is why the alternate routes below exist and why parent-led programs matter.

Designations that help:

The priority review voucher mechanism is worth understanding: it converts a commercially unattractive pediatric rare disease into something with genuine financial upside. It's part of why HG204 attracted a company. This is a legitimate argument to make when approaching industry.

Key terms:

• IND (Investigational New Drug) — the FDA application permitting human dosing.
• Preclinical — everything before humans.
• Toxicology / tox package — formal animal safety studies required before an IND.
• GMP (Good Manufacturing Practice) — the quality standard for material given to humans; a major cost driver.
• Phase 1 / 2 / 3 — safety / efficacy / confirmation.
• Priority Review Voucher (PRV) — a transferable, sellable FDA incentive.

References:

• FDA — Rare Diseases: Resources for Patients
• FDA — Orphan Drug Designation program

23. N-of-1, compassionate use, and bespoke medicines

These are the routes that realistically apply to a child with an ultra-rare duplication.

Route 1 — Off-label use of an approved drug. If the repurposing screen finds an approved medicine, a physician can in principle prescribe it off-label. This is the fastest possible path, and the entire rationale for the fast lane.

But "fastest" is not "casual." Doing it responsibly means:

• a documented scientific rationale,
• a physician willing to prescribe and monitor,
• a pre-specified plan for measuring whether it works (Module 25),
• and ideally a formal N-of-1 design rather than simply starting a drug and watching.

Route 2 — Expanded access / compassionate use. For an unapproved drug, FDA pathways allow access outside a trial for serious conditions. It requires a willing physician, company cooperation, FDA authorization, and institutional ethics approval.

Route 3 — Bespoke ASO (n-Lorem). The n-Lorem Foundation was created specifically for this situation: it develops free, personalized ASOs for "nano-rare" patients — those with mutations affecting very few people worldwide. It is a nonprofit, founded by an ASO field leader, and it is arguably the single most relevant organization in existence for the durable lane in a condition like this one.

Applications come from the treating clinician, not the family directly — which means the practical action is to get a treating physician — typically the clinical geneticist or neurologist — to submit. Eligibility, current capacity, and throughput should be verified directly at the source rather than assumed.

Route 4 — Formal N-of-1 trial. A rigorous single-patient design: pre-specified outcomes, sometimes alternating treatment and non-treatment periods, ideally with blinded assessment. It converts "we tried something and it seemed to help" into evidence others can act on.

Why the rigor is worth it even for one child. Without a pre-specified plan you will not be able to distinguish a real effect from normal developmental variation, placebo response, or the intense hope of everyone involved. Parents and clinicians both systematically over-read improvement in the weeks after starting a treatment — this is well documented and it is not a failing, it's human. Structure is what protects against it, and protects a child from staying on something that isn't working.

Key terms:

• Off-label — prescribing an approved drug for an unapproved indication; legal and common.
• Expanded access / compassionate use — access to an unapproved drug outside a trial.
• N-of-1 trial — a formal single-patient study design.
• Nano-rare — affecting perhaps 1–30 people worldwide.
• IRB / REB — the ethics board that must approve human research.
• Washout period — time off a drug to let effects dissipate before re-testing.
• Pre-registration — publicly stating your outcome measures before collecting data, to prevent unconscious goalpost-moving.

References:

• n-Lorem Foundation — verify current eligibility and application process directly.
• FDA — Expanded Access

24. Why regulators accept low-n evidence in rare disease

Module 11 introduced the evidence hierarchy and noted that ultra-rare disease often cannot reach the top of it. This module explains what regulators do about that — because it directly shapes what your program should be generating.

The problem. A randomized controlled trial in Xq25 duplication syndrome would require far more patients than are known to exist. Demanding one would mean guaranteeing that no therapy is ever developed.

The response. Regulators have developed flexibility for rare disease:

• Acceptance of single-arm studies with historical or natural-history controls.
• Surrogate/biomarker endpoints where a clinical endpoint is impractical.
• Natural history studies as the comparator — which is why documenting the untreated course of a disease has real regulatory value.
• Willingness to engage early and often with sponsors, including academic ones.

What follows for your program. Three things become disproportionately valuable:

1. Natural history data. Careful longitudinal documentation of affected individuals is not merely record-keeping — it is the comparator arm of any future trial.
2. Objective biomarkers. A measurable, objective marker that tracks disease state is worth enormous effort, because it can substitute for a clinical endpoint.
3. Pre-specified, validated outcome measures. Chosen before treatment starts (Module 25).

Key terms:

• Natural history study — documentation of how a disease progresses without treatment.
• Surrogate endpoint — a measurable proxy accepted in place of a clinical outcome.
• Historical control — comparison against previously collected data rather than a concurrent group.
• Single-arm study — everyone receives treatment; no concurrent control group.
• Endpoint — the outcome a study is designed to measure.

References:

• FDA — Rare Diseases: Common Issues in Drug Development guidance

25. Outcome measures, biomarkers, and why baseline matters now

This module describes the most time-sensitive action in the entire program, and it has nothing to do with a laboratory.

The problem. Suppose in two years a drug candidate emerges and your child starts it. Six months later, does the child seem better? Everyone will have an opinion. Without a documented "before," those opinions cannot be turned into knowledge — and you will face the awful position of not knowing whether to continue.

Baselines cannot be created retroactively. This is the one thing that becomes permanently impossible if not done in time. Everything else in this program can be started later; this cannot.

What a baseline should include:

Most families already have some of this — a speech evaluation, a psychology report, an OT or PT assessment done for school or clinical reasons. That material is exactly the right kind of thing. The task is to make it systematic and repeating rather than incidental: the same instruments, at regular intervals, so that a trajectory exists rather than a scattering of isolated snapshots.

On biomarkers. A target-engagement biomarker answers a different and crucial question: is the drug doing what we think, in the body? If STAG2 levels could be measured in an accessible tissue (blood cells, for instance), that would let you confirm the drug is engaging its target — separately from whether the child seems better. This is a valuable thing to ask about, because it decouples "is the mechanism working" from "is the child improving," which otherwise get hopelessly entangled.

Key terms:

• Baseline — documented status before intervention.
• Outcome measure — the pre-specified thing you will assess.
• Validated instrument — a scale with established reliability and norms.
• Target engagement — evidence the drug is acting on its intended target.
• Longitudinal — repeated over time.
• Minimal clinically important difference (MCID) — the smallest change that actually matters to a person's life, as opposed to being statistically detectable.